Kiniksa Pharmaceuticals, Ltd. Appoints Richard S. Levy to Board
March 07, 2019 at 07:53 am EST
Share
Kiniksa Pharmaceuticals, Ltd. announced that on March 4, 2019, the company's Board of Directors increased the number of directors constituting the Board from seven directors to eight directors and appointed Richard S. Levy, M.D. to the Board to fill the vacancy created thereby, all effective immediately. Dr. Levy is a member of the Class I directors, joining Sanj K. Patel and Thomas R. Malley.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
KINIKSA PHARMACEUTICALS, LTD. 
